Natera Launches New WGS Test

Natera said it has launched a new genomic testing platform designed to help diagnose rare diseases faster.​

The test, called Zenith genomics, uses whole genome sequencing to detect genetic changes linked to rare conditions that can be difficult to identify with traditional diagnostic tools. Natera said the technology could help shorten the years-long search many patients experience before receiving a diagnosis.​

“Rare disease patients and their families endure lengthy and costly diagnostic journeys that often delay care and escalate emotional and financial strain,” Meredith Reichert, senior vice president of commercial and general manager of rare disease at Natera, said in a statement. “Zenith has the potential to transform rare disease diagnostics and provide definitive answers to more families.”​

Zenith genomics seeks to address that challenge by analyzing a person’s entire genome, providing a comprehensive view of genetic variations that may contribute to disease. The platform also uses long-read sequencing confirmation to detect complex genetic features, including tandem repeat expansions, that can be difficult to identify with standard sequencing methods.​

Natera unveiled the new platform at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Baltimore, where the company is presenting data on its performance and early clinical use.​

The technology behind Zenith genomics was developed by MyOme, a clinical whole genome analysis company. Through an exclusive partnership, Natera will bring the test to healthcare providers across the United States, using its existing network of electronic medical record integrations and clinical support systems.​

Akash Kumar, chief medical officer at MyOme, said the collaboration will help expand access to advanced genomic sequencing tools. “Partnering with Natera allows us to scale Zenith rapidly and responsibly, ensuring that advanced sequencing tools reach the patients who need them most,” he said.​